Abstract: The present disclosure provides a combination comprising: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable combination thereof. The combination may be used in the treatment and/or prevention of tuberculosis.
Type:
Grant
Filed:
April 7, 2017
Date of Patent:
March 16, 2021
Assignees:
QURETECH BIO AB, WASHINGTON UNIVERSITY IN SAINT LOUIS
Inventors:
Christina L. Stallings, Fredrik Almqvist, Kelly Flentie, James Arthur Dudley Good, Fritiof Ponten
Abstract: In one aspect, the disclosure provides isolated nucleic acids, primers, and probes for the detection of mutations in a nucleic acid sequence for a DICER1 polypeptide.
Type:
Application
Filed:
December 18, 2009
Publication date:
February 16, 2012
Applicants:
THE WASHINGTON UNIVERSITY IN SAINT LOUIS, CHILDREN'S HOSPITAL AND CLINICS OF MINNESOTA
Inventors:
Ashley D. Hill, Paul Goodfellow, John R. Priest, Yoav Messinger